Arrebola-Moreno Antonio L, Casuso Rafael A, Bejder Jacob, Bonne Thomas Christian, Breenfeldt Andersen Andreas, Aragón-Vela Jerónimo, Nordsborg Nikolai B, Huertas Jesús R
Cardiology Department, HLA Inmaculada Hospital, Granada, Spain.
Department of Physiology, Institute of Nutrition and Food Technology, University of Granada, Granada, Spain.
Sports Med Open. 2022 Nov 5;8(1):137. doi: 10.1186/s40798-022-00531-x.
To investigate whether recombinant human erythropoietin (rHuEPO) injections during an altitude training camp impact heart function.
Thirty (12 women) moderately trained subjects stayed at 2320 m altitude for 4 weeks while training. Subjects were randomized to placebo (isotonic saline) or rHuEPO (20 IU/kg body weight) i.v. injections. Transthoracic echocardiography imaging was acquired 3 days after arrival to altitude and prior to the first placebo or rHuEPO injection as well as one day after the last rHuEPO injection three weeks later.
rHuEPO did not alter cardiovascular morphology parameters, systolic or diastolic function. In the placebo group, altitude exposure improved left ventricle (LV) systolic function due to an increased twist angle but rHuEPO had no additional effects. Pulmonary arterial systolic pressure was unaffected in either group. Notably, rHuEPO hampered LV untwist rate without affecting LV early filling.
rHuEPO provided during mild altitude exposure does not cause any major effects on heart function. The observed alteration in LV untwist induced by rHuEPO is unlikely to have a meaningful clinical effect. Trial Registration Registered on www.
gov (NCT04227665).
研究在高原训练营期间注射重组人促红细胞生成素（rHuEPO）是否会影响心脏功能。
30名（12名女性）中度训练的受试者在海拔2320米的高度停留4周，同时进行训练。受试者被随机分为接受安慰剂（等渗盐水）或rHuEPO（20国际单位/千克体重）静脉注射。在到达高原3天后、首次注射安慰剂或rHuEPO之前以及3周后最后一次注射rHuEPO一天后，进行经胸超声心动图成像。
rHuEPO未改变心血管形态参数、收缩或舒张功能。在安慰剂组中，由于扭转角度增加，高原暴露改善了左心室（LV）收缩功能，但rHuEPO没有额外影响。两组的肺动脉收缩压均未受影响。值得注意的是，rHuEPO阻碍了LV解旋速率，而不影响LV早期充盈。
在轻度高原暴露期间提供的rHuEPO对心脏功能没有任何重大影响。观察到的rHuEPO诱导的LV解旋改变不太可能产生有意义的临床效果。试验注册在www.CLINICALTRIALS.gov（NCT04227665）上。
